Written based on 5 research studies on PubMed, searched on 2026. nov. 11..
The claim
Posts online say that CBD (cannabidiol) helps with fatty liver disease (MASLD/MASH).
Where research stands
We found 5 published papers on CBD (cannabidiol) and fatty liver disease (MASLD/MASH). They were published between 2019 and 2026. None of them is a study in people. 3 were studies in animals, and none was only in cells in the lab. 1 paper is a review that sums up other studies.
- 0In people
- 3In animals
- 0Only in the lab
What the studies found
We have not summed up these studies in words yet. The most important papers are listed under Sources.
Verdict
CBD (cannabidiol) has been studied for fatty liver disease (MASLD/MASH) in animals, not yet in people.
Unproven means: it was only tested in animals or cells, or there is too little or mixed data from people. How we rate claims
What this means for you: Results in animals or in cells often do not hold in people. Do not stop or change your medicines because of it. Ask your doctor before you start taking it.
Sources
- The Role of Cannabidiol in Liver Disease: A Systemic Review.2024 · Int J Mol Sci · Review
- Cannabidiolic acid as a modulator of lipid metabolism in the liver of rats with metabolic-associated steatotic liver disease.2026 · Sci Rep · In animals
- The Atypical Cannabinoid Abn-CBD Reduces Inflammation and Protects Liver, Pancreas, and Adipose Tissue in a Mouse Model of Prediabetes and Non-alcoholic Fatty Liver Disease.2020 · Front Endocrinol (Lausanne) · In animals
- Cannabidiol protects livers against nonalcoholic steatohepatitis induced by high-fat high cholesterol diet via regulating NF-κB and NLRP3 inflammasome pathway.2019 · J Cell Physiol · In animals
- Cannabis and Cannabidiol: Pioneering Treatment for the Nervous System with Alzheimer's Disease and Peripheral Organ Involvement with Nonalcoholic Fatty Liver Disease (NAFLD).2025 · Curr Neurovasc Res · Other paper
